STEADFAST: Crizanlizumab plus standard of care vs standard of care in sickle cell nephropathy

Phase 2, randomised, open-label trial in sickle cell nephropathy (SCN) and sickle cell disease (SCD) comparing Crizanlizumab + standard of care with Standard of care alone (2 arms). Primary endpoint: Proportion of patients with ≥30% decrease in ACR at 12 months. Status: unknown.